Industry News

Tonix Pharmaceuticals Holding Corp., Retrophin Inc., Heron Therapeutics Inc., and GW Pharmaceuticals PLC. These companies belong to the Healthcare sector which continues to be defined by drug pricing, scientific advancements, more accommodative regulations, and numerous M&A attempts."/>
Technical Roundup on Drug Makers Stocks -- Tonix Pharma, Retrophin, Heron Therapeutics, and GW Pharma
Masimo announced today the CE marking of the Rad-97™ Pulse CO-Oximeter ®. Rad-97 offers the same Measure-through Motion and Low Perfusion™ SET ® pulse oximetry and upgradeable rainbow SET™ technology as the Radical-7 ® Pulse CO-Oximeter– in a versatile standalone monitor configuration. This Smart News Release features multimedia."/>
Masimo Announces CE Marking of Rad-97™ Pulse CO-Oximeter®
Allscripts Healthcare Solutions, Inc. will report its financial results for the three and nine months ended September 30, 2016, after the close of regular stock market hours on Thursday, November 3, 2016. Allscripts management plans to host a conference call and webcast to discuss the company's earnings and other information at 4:30 p.m. Eastern Standard Time that same day.. More Details on the Third Quarter 2016 Financial Results Call."/>
Allscripts to release third quarter 2016 financial results November 3
Seattle Genetics, Inc. announced today that it will report its third quarter 2016 financial results on Thursday, October 27 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:."/>
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2016 Financial Results on October 27, 2016
Aurinia Pharmaceuticals Inc. a clinical stage biopharmaceutical company focused on the global immunology market, today announced 24- week data in all 10 patients from the AURION study, an open-label exploratory study to assess the short-term..."/>
Aurinia Releases Open-Label AURION Data Demonstrating Increased Remission Rates over Time for Voclosporin in the Treatment of Lupus Nephritis
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that Catabasis is presenting positive data from Part A of the MoveDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy at the World Muscle Society Congress. The World Muscle Society Congress is being held October 4– October 8, 2016, in Granada, Spain, at the Palacio de Congresos de Granada. Joanne Donovan, M.D., Ph.D., Chief Medical Officer of..."/>
Catabasis Pharmaceuticals Presents Positive Data from Part A of the MoveDMD® Trial of Edasalonexent (CAT-1004), a Potential Disease-Modifying Therapy for DMD, at the World Muscle Society Congress
Interpace Diagnostics Group, a provider of molecular diagnostic tests and pathology services, has completed its initial launch of PanDNA ®, a new product that stratifies patients' risk of developing pancreatic cancer based on three specific molecular criteria. PanDNA was developed using the Company's proprietary database of results for over 15,000 patients with pancreatic cysts. Annually, over 170,000 patients in the US are..."/>
Interpace Diagnostics Launches New Streamlined Molecular Product for Pancreatic Cysts
St. Jude Medical Infinity™ Deep Brain Stimulation system and its DBS directional leads, the first directional lead approved in the United..."/>
St. Jude Medical Announces U.S. Launch and First Implant of New Deep Brain Stimulation System and Directional Lead for Patients Suffering from Movement Disorders
AbbVie, a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc., today announced that new data from two replicate Phase 3 studies evaluating the efficacy and safety of Elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, in premenopausal women with endometriosis, will be presented at the upcoming 72 nd American Society for Reproductive Medicine Scientific..."/>
AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix and Research on the Economic Burden of Endometriosis at the 72nd American Society for Reproductive Medicine Scientific Congress
Abiomed, Inc. announced that on Thursday, October 27, 2016, the Company will release financial results for the second quarter of fiscal 2017. The Company will host a conference call to discuss the results on Thursday, October 27, 2016, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer; Michael Tomsicek, Vice President and Chief Financial Officer, will host the conference call.."/>
Abiomed Second Quarter Fiscal 2017 Earnings and Conference Call Notification
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today announced that an abstract describing results from a study evaluating the activity of MBX-8025 in reversing non-alcoholic steatohepatitis in diabetic obese mice has been accepted for an oral presentation at the Annual Meeting of the American Association for the Study of Liver..."/>
CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclincal Model of NASH at the AASLD 2016 Liver Meeting
OmniComm Systems, Inc., a global leading provider of clinical data management technology, today announced that Scientia Clinical Research, Australia’ s newest and most advanced early phase clinical trial facility at the University of New South Wales in Sydney, Australia has selected OmniComm’ s TrialOne clinic automation and eSource application. Scientia Clinical Research is the first purpose built early phase clinical trials center in..."/>
OmniComm Systems Announces First Australia Client
Advaxis, Inc., a clinical stage biotechnology company developing cancer immunotherapies, today announced that Robert Petit, Ph.D., executive vice president and chief scientific officer of Advaxis, was invited to speak at the Immune Profiling World Congress in Barcelona on October 10– 12, 2016.. Petit will deliver a lecture entitled,“ Realizing the promise of neoantigens: Using live attenuated bacteria to generate personalized cancer..."/>
Advaxis CSO Invited to Speak at Immune Profiling World Congress
Editas Medicine, Inc., a leading genome editing company, announced today the grant of an inducement award to the company’ s newly appointed Chief Medical Officer, Gerald F. Cox, M.D., Ph.D. The award was approved by Editas’ Board of Directors on October 5, 2016 as an inducement material to Dr. Cox entering into employment with Editas, in accordance with NASDAQ Listing Rule 5635 (c).."/>
Editas Medicine Reports Inducement Grant to New Chief Medical Officer
Teva Pharmaceutical Industries Ltd., Celltrion, Inc. and Celltrion Healthcare today announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion’ s mAb biosimilar..."/>
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
ICU Medical Inc. management conference call today at 8:30 am EDT, details below SAN CLEMENTE, Calif. and NEW YORK, Oct. 06, 2016-- ICU Medical Inc. and Pfizer..."/>
ICU Medical Inc. to Acquire the Hospira Infusion Systems Business from Pfizer Inc. for $1 Billion in Cash and Stock
AngioDynamics disclosed on Wednesday that it achieved net income of USD1.3m for the 2017 fiscal first quarter ended 31 August 2016.. This represents an improvement when compared witb a net loss of USD0.8m in the first quarter of fiscal 2016. The company added that the first quarter fiscal 2017 net income is driven by volume growth and continued margin improvement."/>
AngioDynamics swings to net income of USD1.3m for Q1 fiscal 2017
Arrowhead Pharmaceuticals Inc. and Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced an agreement to perform collaborative studies on Arrowhead’ s ARC-520 and Spring Bank’ s SB 9200, for the treatment of chronic Hepatitis B. The companies plan to first conduct preclinical models with both..."/>
Arrowhead and Spring Bank Announce Clinical Collaboration for ARC-520 and SB 9200 in Chronic Hepatitis B
PTC Therapeutics, Inc. today announced new data supporting the potential benefit of ataluren in preserving lung function in non-ambulatory nonsense mutation Duchenne muscular dystrophy patients. The results, which are being presented today as part of a company-sponsored symposium, are based on PTC's analyses of lung function data from one of PTC's ongoing open-label extension studies versus natural history data from a..."/>
PTC Therapeutics Announces New Analyses that Support the Potential Benefit of Ataluren in Preserving Lung Function in Non-Ambulatory Nonsense Mutation Duchenne Muscular Dystrophy Patients
WellCare Health Plans revealed on Wednesday the launch of an agreement to acquire Care1st Arizona from Care1st Health Plan for a purchase price of approximately USD157.5m, inclusive of statutory capital and subject to certain adjustments. Care1st Health Plan, an affiliate of Blue Shield of California, was founded by a group comprised of providers, organized medical groups and hospitals with the heart of the community at the forefront of their..."/>
WellCare to buy Care1st Health Plan Arizona for USD157.5m

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology779 Articles
Consumer Discretionary671 Articles
Financials565 Articles
Health Care480 Articles
Industrials421 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at